01Do Not Confuse QC With QA ── Drawing the Line

QA fails on most production floors because it becomes QC's "one more time." The same person, with the same eyes, runs down the same checklist twice. That is duplicated inspection, not assurance.

QC (Part 7, Proofreading and Consistency Inspection) looks at internal quality — was it built to spec? Typos, broken links, figure numbers, transcribed values, tone. QA looks at external fitness — can this be released against the four regulatory tiers (the Act, the Advertising Standards, the MSA Guidelines, the JPMA Code), and is the client's intent realized?

DimensionQC (Gate C)QA (Gate D)
QuestionBuilt to spec?May it be released?
OwnerProofreader / consistency checkerQA reviewer (not the author)
BaselineManuscript, spec, style guideFour regulatory tiers + intent + QC record
OutputDefect list, corrected draftShip/return decision + sign-off
Failure modeA typo survivesA non-compliant asset ships
Principle: QA is not a re-run of QC. Once QC has assured that the work was built correctly, QA judges only whether it may be released. Deliverables with QC incomplete do not go up to QA.

02Independence ── The Author Never Says "Ship It"

The spine of the QA SOP fits in one line: separate the author from the QA reviewer. This is not about trust or distrust; it is about the structure of cognition. A writer cannot see the logical gaps in their own prose. Someone convinced they have met the client's intent cannot test the possibility that they have not. When Generator and Evaluator are the same person, evaluation collapses into self-justification.

Independence levelSetupAcceptable for
L3 FullQA in a separate team and reporting lineApproved assets; first issue of a new brand
L2 RoleSame team, author ≠ QA reviewerRevisions; reuse of existing templates
L1 TimeSame person, 48h+ gap, different checklistMinor fixes / internal docs only (never promotional assets)
NG

Deadline looming, the director who built it fills in the QA checklist themselves, signs "no issues," and reports "double-checked" to the client.

OK

The director goes only as far as QC. A separate reviewer with no stake in the job starts QA after receiving the QC record, catches two returns, and signs only after fixes are applied.

Principle: Never use L1 for promotional or approved pharma assets. L2 is the floor; the first issue of an approved asset requires L3.

03Gate D Pass Criteria ── What Earns a "Ship It"

Never sign on "probably fine." Pass criteria are written down in advance, and nothing passes unless every item is PASS. The criteria are ordered in three tiers — regulatory fit, then scientific accuracy, then realization of intent — matching the definition of quality set out in Part 1.

  1. Regulatory fit (mandatory; a single NG forces a return): Indications and dosage within the approved range. No exaggerated or absolute claims (Act §66). No advertising of unapproved drugs or off-label use (§68). Information provision kept distinct from advertising and meeting the request-based requirements (§68-2 / MSA Guidelines). Comparative, safety, and economic claims compliant with the Advertising Standards. Procedural requirements of the JPMA Code / creation guide (approval number, citation, conflict of interest) satisfied.
  2. Scientific accuracy: Every claim tied to a source. Citations match the originals (no alteration or cherry-picking). Population, conditions, and limitations stated. QC record present.
  3. Realization of intent: Meets the SOW and concept fixed at Gate A. Fits the target reader, use scene, and channel requirements.
Principle: Regulatory fit cannot be weighted. No matter how strong the science or intent, one regulatory NG makes the whole NG. Do not reverse the order.

04The QA Checklist (The SOP Itself)

File the following with the job record, leaving a verdict (P/F/N-A), reviewer initials, and the means of verification (source page number, etc.) for each item. A signature over any blank item is void.

#ItemBasisVerdict
D-1Indications/dosage within label / approved rangeAct §66 / Ad Reg 01P/F
D-2No exaggerated, superlative, or absolute safety claimsAd Standards 03P/F
D-3No advertising of unapproved / off-label useAct §68P/F
D-4Information provision distinct from advertising; request/limited-provision requirementsAct §68-2 / MSA-G 04P/F
D-5Comparative / economic claims compliantMSA-G Q&A 05P/F
D-6JPMA Code / creation guide procedural requirements met06 / 07P/F
D-7Every claim sourced; citations match originalsScientific accuracyP/F
D-8QC completion record (Gate C) attachedPart 7P/F
D-9SOW / concept (Gate A) satisfiedPart 2P/F
D-10Channel, version, revision number, release scope match the briefTraceability (Part 10, in prep)P/F

When using N-A (not applicable), leave a one-line reason, e.g. "D-5: contains no comparative claims, N-A." An N-A without a reason is treated as F.

05The Ship-or-Return Logic ── Three Exits

QA has exactly three exits. Do not let a vague "conditional OK" pass by word of mouth; force every case into this taxonomy.

VerdictConditionNext action
PASS (ship)D-1 through D-10 all PQA sign-off → delivery process
RETURNOne or more F in regulatory items (D-1–D-6), or a serious F in science/intentIssue a defect ticket and return to author. Re-QA after fixes
ESCALATEThe verdict is gray (regulatory reading is split / no precedent / intent collides with regulation)Route per Section 06. QA does not sign alone
NG

D-4 (provision vs. advertising) was gray, but with the deadline first, the reviewer self-judged "probably fine" and marked PASS. Later flagged as advertising in an MR-distributed asset and recalled.

OK

The moment D-4 read as gray, the reviewer did not PASS but ESCALATEd, queried regulatory/medical-legal, amended the wording, then RETURN → re-QA → PASS. The decision and basis were recorded on the job sheet.

Principle: When in doubt, do not PASS. Gray means ESCALATE. QA silence is not "OK" — it is "undecided."

06Escalation Routes ── To Whom, What, and When

Settling escalation as "ask the boss" leaves no record of the reasoning and does not reproduce. Fix the route, trigger, and record in the SOP.

TriggerEscalate toAttach
Split regulatory reading (D-1–D-6 gray)In-house regulatory / medical-legalPassage, article, both readings, QA tentative verdict
Intent collides with regulationClient's regulatory reviewer + sales contactIntent, conflicting article, two alternatives
Unprecedented channel/expressionQA lead → external regulatory consultant if neededExplanation of novelty, similar cases
Unresolvable within deadlinePM + client (renegotiate timeline)Risk, earliest resolution date, interim plan

Always attach the QA reviewer's tentative verdict. Do not toss the decision upward; present your read and its basis, then ask the senior party to confirm — this raises both the quality and the speed of the answer. Record the response on the job sheet and accumulate it as precedent for similar cases.

07The QA Sign-Off ── What the Signature Stands For

A signature is not a formality; it makes responsibility explicit. It records who, when, and on what basis said "ship it." At minimum, the signature block carries:

Principle: The signature is bound to the version. Replace a single character of text or image after sign-off and that version's signature lapses, requiring re-QA. Quietly passing a "post-signature edit" is a breach of discipline.

Even after sign-off, a newly surfaced regulatory amendment, recall case, or label revision triggers a retroactive re-QA. The signature is assurance at a point in time, not a perpetual guarantee.

08Running QA ── Records, Metrics, Improvement

An SOP becomes quality only once it is operated. Measure and improve the QA process itself.

These connect to traceability in the next process (Part 10, in prep). Only when you can trace which version, by whom, and on what basis it was passed does post-leakage investigation and recurrence prevention become possible. The QA SOP does not stand alone; it works by connecting to the records of the whole lifecycle.

Key Points ── Three to Take Away
  1. QA is not a QC re-run but a judgment of whether something may be released. Separating author from reviewer is the spine of the SOP: pharma assets need L2 at minimum, an approved asset's first issue needs L3.
  2. Gate D criteria run regulatory fit → scientific accuracy → realized intent. Regulatory items (D-1–D-6) cannot be weighted; one NG fails the whole. There are only three exits — PASS, RETURN, ESCALATE — and gray never passes.
  3. The QA sign-off is responsibility bound to a version; a one-character edit after sign-off voids it and forces re-QA. Track return rate and leakage, and connect to traceability to keep improvement running.
Sources & References
  1. MHLW, Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices (PMD Act) (article-by-article reading of §66, §68, §68-2). Primary basis for drug advertising regulation.
  2. MHLW, Standards for Fair Advertising of Drugs (PSEHB Notification 0929-4, 29 Sep 2017). Criteria for comparative, safety, and economic claims.
  3. MHLW, Guidelines on Sales Information Provision Activities for Prescription Drugs (MSA Guidelines). Distinction between information provision and advertising, and procedural requirements.
  4. JPMA, Code of Practice for Prescription Drug Promotion and JPMA Creation Guide. Industry self-regulation and procedural requirements for material creation.
  5. K. Iida et al., Practice of Pharmaceutical Advertising Review, Yakuji Nippo. Review-practice criteria and return cases.
  6. JSA, ISO 9001:2015 Requirements Explained (Quality Management Systems). General principles of verification, validation, and records control.
  7. N. Tanahashi, Writing Quality-Control SOPs for the Field, JUSE Press. Practical SOP design, sign-off, and deviation control.